RadComp Newsletter - June 2025

RadComp™

PATIENT POWERED

A study at the heart of breast cancer treatment

Study News



Change of Principal Investigators at Massachusetts General Hospital

Dr. Shannon MacDonald is moving on from her role as Site Principal Investigator at Massachusetts General Hospital, a role she has had since 2015, but her involvement in RadComp goes back even farther.

Read More
Congratulate Dr. MacDonald



Massachusetts General Hospital's New Site PI, Dr. Rachel Jimenez

Dr. Rachel Jimenez took over the reins as site Principal Investigator on June 1, 2025. She has been a leading enroller for the RadComp Study from 2016 to 2024. In addition to helping RadComp reach its enrollment goals, Dr. Jimenez is pursing corollary research goals.

Read More
Congratulate Dr. Jimenez

Publication of Interest



Congratulations to
RadComp Stakeholder Advisory Member **Cynthia Chauhan, MSW,** on her recent publication

Heart Failure in Patients with Cancer – A Patient's Perspective

Journal of Cardiac Failure,
Volume 31, Issue 2, February 2025

Congratulate Cynthia Chauhan


Advocacy Partner Events & Resources


Save the Date
PCORI Annual Meeting
Registration opens on July 7th


Date: Oct. 21 - 22, 2025, All Day (ET)

Location: JW Marriott, 1331 Pennsylvania Avenue NW, Washington, DC, 20004

Read More









YSC Virtual Hangouts

YSC Virtual Hangouts are protected spaces where survivors, thrivers and co-survivors can come together and share their experiences.

Each Virtual Hangout is co-led by a survivor, thriver or co-survivor and a licensed clinical social worker (LCSW) to increase your access to tailored support.

Click here to register and learn more

Cancer Support Community Educational Resources

Cancer Support Community offers a host of patient focused educational materials that may be of interest to you.

Click here to learn more

More About RadComp



Visit our website

Study Locations

Clinicaltrials.gov

This newsletter was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-1403-12804). The views, statements, and opinions presented are solely the responsibility of the author(s) and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee.

The RadComp Study Coordinating Center, University of Pennsylvania, Penn Medicine | 3400 Civic Center Blvd. | Philadelphia, PA 19104 US

Unsubscribe | Update Profile | Constant Contact Data Notice

Constant Contact

Try email marketing for free today!

Change of Principal Investigators at Massachusetts General Hospital



Dr. Shannon MacDonald is moving on from her role as RadComp's Site Principal Investigator at Massachusetts General Hospital, a role she has had since the Study began in November 2015. However, her involvement in RadComp goes back much farther. Along with Justin Bekelman of Penn Medicine and Oren Cahlon, formerly of Memorial Sloan Kettering, Shannon MacDonald is a founding member of the RadComp Study, assisting in the design of the Study and helping to write the study proposal prior to 2015.

She is a founding and current member of the RadComp Executive Committee and RadComp's clinical chair. She will continue to serve in these roles. Additionally, she serves as co-chair of the RadComp Publications Committee.

Dr. MacDonald has taken on a new role as Medical Director for Southwest Florida Proton, where she will work with the management team to oversee clinical operations. Later this year, she and her team will begin delivering the first proton therapy treatments at this facility. (Felix, 2025)

Dr. MacDonald has turned over her position as RadComp Site Principal Investigator to Dr. Rachel Jimenez, a leading enrolling physician on the Study.

Congratulate Dr. MacDonald

References

Felix, C. (2025, January 15). *Southwest Florida Proton hires Dr. Shannon MacDonald as medical director.* Retrieved from South Florida Hospital News Report: https://southfloridahospitalnews.com/southwest-florida-proton-hires-dr-shannon-macdonald-as-medical-director/

Massachusetts General Hospital's New Site PI, Dr. Rachel Jimenez



Dr. Rachel Jimenez took over the reins as site Principal Investigator for the RadComp's Massachusetts General Hospital enrollment site on June 1, 2025. During RadComp's enrollment phase, between 2016 and 2024, Dr. Jimenez was consistently one of RadComp's top enrolling physicians. In addition to helping RadComp reach its enrollment goals, Dr. Jimenez is pursing corollary research goals. Her research study called, **"The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients",** is designed to study the same participant population as the RadComp Study, for participants from the Massachusetts General Hospital site only.

The study's primary objective is to measure early cardiac changes by non-invasive cardiac assessments between conventional radiation and proton radiation.

Other outcomes of interest include:

- radiation-induced lung parenchymal changes
- incidence of thyroid insufficiency in each radiation group
- Incidence of ipsilateral arm lymphedema in each radiation groups
- Breast/chest wall cosmesis and reconstructive complication

As with RadComp, the enrollment phase of Dr. Jimenez's research project is now complete, and the study is in long-term follow-up until all study aims are completed.

References

Jimenez, R. (2025, June 23). *The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients*. Retrieved from ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT03270072?term=proton%20randomized&aggFilters=status:rec&country=United%20States&locStr=United%20States&viewType=Table&rank=6